India, Sept. 5 -- Glenmark Pharmaceuticals Ltd., a research-driven global pharmaceutical company, has announced the initiation of a multi-country (ex-China) Phase 3 clinical trial of Envafolimab, a novel subcutaneous PD-L1 inhibitor, in patients with resectable Stage III Non-Small Cell Lung Cancer (NSCLC) in the neoadjuvant/adjuvant setting.
The company has received approval from the Drugs Controller General of India (DCGI) to begin patient enrollment and dosing in India. Additionally, Glenmark has submitted a Clinical Trial Application (CTA) in Russia and is preparing to open further trial sites in Brazil and Mexico, expanding the global reach of this pivotal study.
This randomized, multi-center Phase 3 trial will evaluate the efficacy, ...